

# Richard E Gilbert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11455510/publications.pdf>

Version: 2024-02-01

107  
papers

9,648  
citations

31902

53  
h-index

37111

96  
g-index

107  
all docs

107  
docs citations

107  
times ranked

10945  
citing authors

#	ARTICLE	IF	CITATIONS
1	The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?. <i>Kidney International</i> , 1999, 56, 1627-1637.	2.6	566
2	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. <i>Canadian Journal of Cardiology</i> , 2018, 34, 506-525.	0.8	474
3	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 549-568.	0.8	431
4	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2016, 32, 569-588.	0.8	400
5	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2019, 140, 1693-1702.	1.6	371
6	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. <i>Canadian Journal of Cardiology</i> , 2017, 33, 557-576.	0.8	269
7	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. <i>Lancet</i> , 2015, 385, 2107-2117.	6.3	240
8	The (Pro)Renin Receptor. <i>Hypertension</i> , 2009, 54, 261-269.	1.3	234
9	Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease. <i>Diabetes</i> , 2017, 66, 791-800.	0.3	231
10	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2020, 141, 704-707.	1.6	225
11	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 485-501.	0.8	221
12	Retinal Neovascularization Is Prevented by Blockade of the Renin-Angiotensin System. <i>Hypertension</i> , 2000, 36, 1099-1104.	1.3	216
13	Direct Actions of Urotensin II on the Heart. <i>Circulation Research</i> , 2003, 93, 246-253.	2.0	196
14	Transforming growth factor $\beta$ 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. <i>Kidney International</i> , 1997, 51, 1553-1567.	2.6	192
15	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 "therapy". <i>Canadian Journal of Cardiology</i> , 2010, 26, 249-258.	0.8	191
16	Protein Kinase C $\alpha$ Inhibition Attenuates the Progression of Experimental Diabetic Nephropathy in the Presence of Continued Hypertension. <i>Diabetes</i> , 2003, 52, 512-518.	0.3	173
17	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. <i>Canadian Journal of Cardiology</i> , 2012, 28, 270-287.	0.8	173
18	Are $\beta$ -blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. <i>American Heart Journal</i> , 2003, 146, 848-853.	1.2	170

#	ARTICLE	IF	CITATIONS
19	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2013, 29, 528-542.	0.8	163
20	Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. <i>Journal of Hepatology</i> , 2001, 35, 376-385.	1.8	159
21	Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14448-14453.	3.3	137
22	Long-Term Administration of the Histone Deacetylase Inhibitor Vorinostat Attenuates Renal Injury in Experimental Diabetes through an Endothelial Nitric Oxide Synthase-Dependent Mechanism. <i>American Journal of Pathology</i> , 2011, 178, 2205-2214.	1.9	134
23	Pathological Expression of Renin and Angiotensin II in the Renal Tubule after Subtotal Nephrectomy. <i>American Journal of Pathology</i> , 1999, 155, 429-440.	1.9	132
24	Demographics and concomitant disorders in heart failure. <i>Lancet, The</i> , 2003, 362, 147-158.	6.3	127
25	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. <i>Canadian Journal of Cardiology</i> , 2011, 27, 415-433.e2.	0.8	127
26	Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. <i>Kidney International</i> , 2000, 58, 2437-2451.	2.6	120
27	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. <i>Canadian Journal of Cardiology</i> , 2009, 25, 287-298.	0.8	111
28	Inhibition of Platelet-Derived Growth Factor Promotes Pericyte Loss and Angiogenesis in Ischemic Retinopathy. <i>American Journal of Pathology</i> , 2004, 164, 1263-1273.	1.9	108
29	Aminoguanidine Ameliorates Overexpression of Prosclerotic Growth Factors and Collagen Deposition in Experimental Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2098-2107.	3.0	108
30	Urinary Connective Tissue Growth Factor Excretion in Patients With Type 1 Diabetes and Nephropathy. <i>Diabetes Care</i> , 2003, 26, 2632-2636.	4.3	103
31	Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-?. <i>Cardiovascular Research</i> , 2005, 65, 694-701.	1.8	102
32	Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. <i>Kidney International</i> , 2011, 79, 1312-1321.	2.6	102
33	The Renin-Angiotensin System Influences Ocular Endothelial Cell Proliferation in Diabetes. <i>American Journal of Pathology</i> , 2003, 162, 151-160.	1.9	100
34	COX-2 Inhibition and Retinal Angiogenesis in a Mouse Model of Retinopathy of Prematurity. , 2003, 44, 974.		98
35	Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2) <sup>27</sup> rat. <i>Kidney International</i> , 2000, 57, 1882-1894.	2.6	96
36	Expression, Localization, and Function of the Thioredoxin System in Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 730-741.	3.0	96

#	ARTICLE	IF	CITATIONS
37	Blockade of the Renin-Angiotensin and Endothelin Systems on Progressive Renal Injury. Hypertension, 2000, 36, 561-568.	1.3	93
38	Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney International, 2014, 86, 693-700.	2.6	93
39	Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney International, 1993, 44, 855-859.	2.6	89
40	The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. Journal of Clinical Investigation, 2012, 122, 759-776.	3.9	86
41	Protein Kinase C $\beta$ Inhibition Attenuates Osteopontin Expression, Macrophage Recruitment, and Tubulointerstitial Injury in Advanced Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2005, 16, 1654-1660.	3.0	84
42	Osteopontin expression in progressive renal injury in remnant kidney: Role of angiotensin II. Kidney International, 2000, 58, 1469-1480.	2.6	81
43	Renal expression of transforming growth factor- $\beta$ 2 inducible gene-h3 ( $\beta$ ig-h3) in normal and diabetic rats11See Editorial by Border and Noble, p. 1390.. Kidney International, 1998, 54, 1052-1062.	2.6	79
44	Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy. Kidney International, 1999, 56, S31-S36.	2.6	79
45	Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney International, 2002, 61, 31-39.	2.6	76
46	Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney International, 2001, 60, 715-721.	2.6	75
47	Endothelin Receptor Antagonism Ameliorates Mast Cell Infiltration, Vascular Hypertrophy, and Epidermal Growth Factor Expression in Experimental Diabetes. Circulation Research, 2000, 86, 158-165.	2.0	72
48	High Glucose-Induced Thioredoxin-Interacting Protein in Renal Proximal Tubule Cells Is Independent of Transforming Growth Factor- $\beta$ 21. American Journal of Pathology, 2007, 171, 744-754.	1.9	71
49	Mast cell infiltration and chemokine expression in progressive renal disease1. Kidney International, 2003, 64, 906-913.	2.6	69
50	Diabetes-Induced Vascular Hypertrophy Is Accompanied by Activation of Na <sup>+</sup> -H <sup>+</sup> Exchange and Prevented by Na <sup>+</sup> -H <sup>+</sup> Exchange Inhibition. Circulation Research, 2000, 87, 1133-1140.	2.0	63
51	Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Cardiovascular Research, 2018, 114, 1629-1641.	1.8	63
52	Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 193-208.	2.2	58
53	Culture-Modified Bone Marrow Cells Attenuate Cardiac and Renal Injury in a Chronic Kidney Disease Rat Model via a Novel Antifibrotic Mechanism. PLoS ONE, 2010, 5, e9543.	1.1	55
54	DIABETIC VASCULAR COMPLICATIONS.. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 770-775.	0.9	54

#	ARTICLE	IF	CITATIONS
55	Trilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H2860-H2869.	1.5	54
56	Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. <i>Nephrology</i> , 2011, 16, 573-581.	0.7	54
57	SB-267268, a Nonpeptidic Antagonist of $\alpha_3$ and $\alpha_5$ Integrins, Reduces Angiogenesis and VEGF Expression in a Mouse Model of Retinopathy of Prematurity. , 2006, 47, 1600.		53
58	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1164-1173.	2.3	51
59	Transforming Growth Factor- $\beta$ in Human Diabetic Nephropathy: Effects of ACE inhibition. <i>Diabetes Care</i> , 2006, 29, 2670-2675.	4.3	50
60	Macrophage Infiltration and Cellular Proliferation in the Non-Ischemic Kidney and Heart following Prolonged Unilateral Renal Ischemia. <i>Nephron Physiology</i> , 2007, 106, p54-p62.	1.5	47
61	Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0144640.	1.1	47
62	Pathophysiology of diabetic nephropathy. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 3-6.	1.5	46
63	Sirtuin 1 Activation Reduces Transforming Growth Factor- $\beta$ -Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. <i>American Journal of Pathology</i> , 2017, 187, 80-90.	1.9	42
64	Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. <i>Cardiovascular Diabetology</i> , 2020, 19, 13.	2.7	42
65	SDF-1/CXCR4 Signaling Preserves Microvascular Integrity and Renal Function in Chronic Kidney Disease. <i>PLoS ONE</i> , 2014, 9, e92227.	1.1	39
66	The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. <i>Journal of Hypertension</i> , 2011, 29, 1175-1184.	0.3	37
67	A Purpose-Synthesised Anti-Fibrotic Agent Attenuates Experimental Kidney Diseases in the Rat. <i>PLoS ONE</i> , 2012, 7, e47160.	1.1	37
68	Hypertension in people with type 2 diabetes: Update on pharmacologic management. <i>Canadian Family Physician</i> , 2011, 57, 997-1002, e347-53.	0.1	37
69	FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2012, 14, 549-562.	2.9	36
70	SPARC gene expression is reduced in early diabetes-related kidney growth. <i>Kidney International</i> , 1995, 48, 1216-1225.	2.6	35
71	Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1286-1292.	0.4	35
72	Early-Outgrowth Bone Marrow Cells Attenuate Renal Injury and Dysfunction via an Antioxidant Effect in a Mouse Model of Type 2 Diabetes. <i>Diabetes</i> , 2012, 61, 2114-2125.	0.3	32

#	ARTICLE	IF	CITATIONS
73	Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. <i>Cardiovascular Diabetology</i> , 2018, 17, 99.	2.7	32
74	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. <i>Circulation</i> , 2018, 137, 88-90.	1.6	30
75	Fluorescent Microangiography Is a Novel and Widely Applicable Technique for Delineating the Renal Microvasculature. <i>PLoS ONE</i> , 2011, 6, e24695.	1.1	29
76	The Interaction between the Renin-Angiotensin System and Vascular Endothelial Growth Factor in the Pathogenesis of Retinal Neovascularization in Diabetes. <i>Journal of Vascular Research</i> , 2001, 38, 527-535.	0.6	26
77	The Endothelium in Diabetic Nephropathy. <i>Current Atherosclerosis Reports</i> , 2014, 16, 410.	2.0	25
78	Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2) <sup>27</sup> rats: Attenuation with renin-angiotensin blockade. <i>Nephrology</i> , 2004, 9, 7-13.	0.7	24
79	Treatment of Diabetes in People With Heart Failure. <i>Canadian Journal of Diabetes</i> , 2018, 42, S196-S200.	0.4	24
80	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 895-897.	0.4	22
81	Protein kinase C- $\alpha$ inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1782-1790.	0.4	21
82	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 644-646.	1.2	18
83	Urinary transforming growth factor- $\beta$ 2 in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2442-2443.	0.4	17
84	Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: Morphological and molecular biological studies. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 24-27.	1.5	16
85	Is there a role for endothelin antagonists in diabetic renal disease?. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, 15-24.	2.2	15
86	Treatment of Hypertension. <i>Canadian Journal of Diabetes</i> , 2018, 42, S186-S189.	0.4	15
87	Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice. <i>American Journal of Pathology</i> , 2018, 188, 2763-2773.	1.9	14
88	Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus. <i>Physiological Reports</i> , 2021, 9, e14890.	0.7	13
89	Role of the eNOS-NO System in Regulating the Antiproteinuric Effects of VEGF Receptor 2 Inhibition in Diabetes. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	12
90	Bone Marrow Cell Therapies for Endothelial Repair and Their Relevance to Kidney Disease. <i>Seminars in Nephrology</i> , 2012, 32, 215-223.	0.6	11

#	ARTICLE	IF	CITATIONS
91	A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 168, 1174-1185.	0.8	11
92	Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies. <i>Acta Diabetologica</i> , 2014, 51, 771-782.	1.2	11
93	Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 200.	2.7	10
94	Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 276-82.	2.3	10
95	Diabetes and Hypertension: Prognostic and Therapeutic Considerations. <i>Blood Pressure</i> , 1995, 4, 329-338.	0.7	8
96	Hyperglycemia and Renal Mass Ablation Synergistically Augment Albuminuria in the Diabetic Subtotally Nephrectomized Rat: Implications for Modeling Diabetic Nephropathy. <i>Nephron Extra</i> , 2012, 2, 115-124.	1.1	4
97	Cell Therapy for Diabetic Nephropathy: Is the Future, Now?. <i>Seminars in Nephrology</i> , 2012, 32, 486-493.	0.6	4
98	Impaired <i>SIRT1</i> activity leads to diminution in glomerular endowment without accelerating age-associated <i>GFR</i> decline. <i>Physiological Reports</i> , 2019, 7, e14044.	0.7	4
99	Late intervention in the remnant kidney model attenuates proteinuria but not glomerular filtration rate decline. <i>Nephrology</i> , 2021, 26, 270-279.	0.7	4
100	Heart failure: fatal, forgotten, and frequent in type 1 diabetes too. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 832-834.	5.5	3
101	Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2016, 17, 147032031666843.	1.0	2
102	Vasoactive Molecules and the Kidney. , 2012, , 384-420.		2
103	Application of Modular Therapy for Renoprotection in Experimental Chronic Kidney Disease. <i>Tissue Engineering - Part A</i> , 2015, 21, 1963-1972.	1.6	1
104	Angiotensin-converting enzyme inhibition attenuates renal platelet-derived growth factor gene expression and cell proliferation in subtotal nephrectomy. <i>Nephrology</i> , 2001, 6, 290-297.	0.7	0
105	Protective role for Epidermal Growth Factor in Advanced Diabetic Nephropathy of Transgenic (mRen2)27 rats. <i>Nephrology</i> , 2000, 5, A102-A102.	0.7	0
106	Protective role for Epidermal Growth Factor in Advanced Diabetic Nephropathy of Transgenic (mRen2)27 rats. <i>Nephrology</i> , 2000, 5, A102-A102.	0.7	0
107	Hypertension revisited. <i>Canadian Family Physician</i> , 2012, 58, 634-6.	0.1	0